← Leaderboards
Renuka Sriram
University Of California, San Francisco
$2,377,614
Attributed
$5,971,308
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,971,308 · 4
By mechanism
U24$3,430,714 · 1
R01$1,959,827 · 1
R21$420,809 · 1
R03$159,958 · 1
Top collaborators
- John Kurhanewicz8 shared
- Donna M Peehl8 shared
- Robert Richard Flavell3 shared
- Youngho Seo3 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Lawrence Fong$19,816,074
- Thomas Hope$3,566,163
- Felix Yi-Chung Feng$6,764,664
- Michael John Evans$10,372,266
- Maurice Marcel Garcia$3,848,190
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsImagePathologicPre-ClinicalResistanceClinical TrialsTreatment ResponseTreatment EfficacyPyruvateMetabolicMagnetic ResonanceImaging TechniquesTumorPatient Derived Xenograft ModelMagnetic Resonance ImagingBiological MarkersBoneLiverMalignant Neoplasm Of ProstateMetastatic Prostate CancerPositron-Emission TomographyClinical ImagingClinical ResearchChemotherapy
Grant awards (15)
Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapy$664,448
R01 · FY2025 · CA
Monitoring response of neoadjuvant therapy in primary bladder cancer using hyperpolarized 13C MRI$191,675
R21 · FY2025 · CA · contact PI
Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapy$631,129
R01 · FY2024 · CA
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI$626,274
U24 · FY2024 · CA
Monitoring response of neoadjuvant therapy in primary bladder cancer using hyperpolarized 13C MRI$229,134
R21 · FY2024 · CA · contact PI
Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapy$664,250
R01 · FY2023 · CA
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI$656,819
U24 · FY2023 · CA
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI$74,419
U24 · FY2023 · CA
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI$656,818
U24 · FY2022 · CA
Characterization of PDX SCNC prostate cancer metastatic murine models and development of associated research resources$75,937
U24 · FY2022 · CA
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI$670,222
U24 · FY2021 · CA
Preclinical imaging characterization and resource development of PDX SCNC prostate cancer murine models$1
U24 · FY2021 · CA
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI$670,224
U24 · FY2020 · CA
Development of methodologies and probes for metabolic detection of pathogenic microorganisms$80,000
R03 · FY2019 · AI · contact PI
Development of methodologies and probes for metabolic detection of pathogenic microorganisms$79,958
R03 · FY2018 · AI · contact PI